Glenmark Life Sciences Limited

As of December 31, 2024, Glenmark Life Sciences Limited trades at a trailing price-to-earnings ratio of 27.28.

As of December 31, 2024, Glenmark Life Sciences Limited trades at an EV/EBITDA multiple of 21.22 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.54 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 21.22 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Glenmark Life Sciences Limited trades at an EV/FCF ratio of 10,647.04, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of December 31, 2024, Glenmark Life Sciences Limited maintains a current ratio of 8.89, meaning it holds 8.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.36, indicating moderate leverage, while an interest coverage ratio of 374.02 demonstrates strong ability to service its debt obligations.

These figures cover the twelve months ended December 31, 2024. Return on capital employed (ROCE) is 1,055.38, useful for judging operating efficiency across full business cycles.

These figures cover the twelve months ended December 31, 2024. That works out to an effective tax rate of 25.45, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items.

Over the twelve months ended December 31, 2024, Glenmark Life Sciences Limited posted a gross margin of 51.48, reflecting its pricing power and cost economics. The operating margin of 26.10 and net profit margin of 20.30 provide insight into operational efficiency.

As of December 31, 2024, Glenmark Life Sciences Limited has an Altman Z-Score of 18.90, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.